{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "BACKGROUND: Patients scheduled for thoracic cancer surgery are eligible for goal-directed fluid therapy, but cardiac output monitoring remains challenging in that specific setting."
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "DESIGN: A prospective monocentre observational study."
      },
      "Participants": {
        "score": 2,
        "evidence": "PATIENTS: Fifty adult patients undergoing thoracic cancer surgery over a one year period."
      },
      "Intervention": {
        "score": 2,
        "evidence": "We aimed to compare cardiac output as measured with chest bioreactance with that measured by calibrated pulse contour analysis."
      },
      "Objective": {
        "score": 1,
        "evidence": "OBJECTIVE: We aimed to compare cardiac output as measured with chest bioreactance with that measured by calibrated pulse contour analysis; the hypothesis being that both methods would be interchangeable."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "MAIN OUTCOME MEASURES: Simultaneous measurements of cardiac index (CI) with bioreactance (CI-NICOM) and arterial pulse contour analysis calibrated by transthoracic echocardiography (CI-PCA) were performed at eight pre-specified intra-operative time points and following fluid challenge and/or vasoactive agents."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "PATIENTS: Fifty adult patients undergoing thoracic cancer surgery over a one year period."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "RESULTS: There was a significant difference between CI-PCA and CI-NICOM: 2.4\u200a\u00b1\u200a0.8 (range: 0.9 to 5.8) l\u200amin \u22121 m \u22122 vs. 2.9\u200a\u00b1\u200a0.9 (range: 0.9 to 7.2) l\u200amin \u22121 m \u22122 , respectively ( P <\u200a0.001)."
      },
      "Harms": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "TRIAL REGISTRATION: NCT04251637 ."
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 12,
    "max_score": 25
  },
  "model": "gpt-4o"
}